Allon Receives European Orphan Drug Status for Davunetide

Allon Therapeutics Inc. announced Wednesday that its lead neuroprotective drug candidate, davunetide, has been granted Orphan Drug Status in the European Union for the treatment of Progressive Supranuclear Palsy, a rapidly-progressing and fatal degenerative brain disease.
Fox Business